Results 31 to 40 of about 1,494 (190)

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells [PDF]

Nature Communications, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic malignancy derived from the precursors of plasmacytoid dendritic cells.
Tianyu Cai, Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor, Ming Zhao, Qi Yuan, Mayumi Sugita, Qi Zhang, Roman Galetto, Stéphanie Filipe, Antonio Cavazos, Lina Han, Vinitha Kuruvilla, Helen Ma, Connie Weng, Chang-Gong Liu, Xiuping Liu, Sergej Konoplev, Jun Gu, Guilin Tang, Xiaoping Su, Gheath Al-Atrash, Stefan Ciurea, Sattva S. Neelapu, Andrew A. Lane, Hagop Kantarjian, Monica L. Guzman, Naveen Pemmaraju, Julianne Smith, Andrei Thomas-Tikhonenko, Marina Konopleva   +32 more
doaj   +2 more sources

Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report [PDF]

Clinical Pathology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive neoplastic process of precursor plasmacytoid dendritic cells. The diagnostic evaluation of this heterogenous entity is challenging, requiring a comprehensive approach of ...
Jasper X Zheng, Elham Vali Betts, Denis M Dwyre, Jong H Chung, Ananya Datta Mitra   +4 more
doaj   +2 more sources

Hematopoietic effects of tagraxofusp in treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]

Cancer
Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, Vasu S, Rosenblat T, Zuurman M, Gupta I, Lane AA.   +10 more
europepmc   +2 more sources

Radiation Therapy for Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report and Review of the Literature

Current Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a clinically aggressive hematologic malignancy derived from plasmacytoid dendritic cells. It commonly presents as cutaneous lesions.
Masashi Taka, Shinichiro Toyoshima, Shigeyuki Takamatsu, Satoshi Kobayashi   +3 more
doaj   +2 more sources

A phase 1 trial of CD123-directed chimeric antigen receptor T-cell therapy in adults with relapsed/refractory acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm [PDF]

Journal of Hematology & Oncology
Background Patients with relapsed acute myeloid leukemia (AML), particularly following allogeneic stem cell transplant (alloHCT), have extremely limited therapeutic options.
Lihua E. Budde, Marissa M. Del Real, Joo Song, Tracey Stiller, Yan Wang, Ahmed Aribi, Karamjeet Sandhu, Ryotaro Nakamura, Emanuela C. Marcucci, Jian J. Wu, Kenneth Ng, Mary C. Clark, Brent Wood, Jamie R. Wagner, Jinny Paul, Christine E. Brown, Anthony Stein, Guido Marcucci, M. Suzette Blanchard, Joycelynne Palmer, Stephen J. Forman   +20 more
doaj   +2 more sources

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base [PDF]

Leukemia Research Reports
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit ...
Nathan M. Krah, Rasmus Hoeg, Paul J. Shami, Shannon E. Elf, Lauren E. Lee, Naveen Pemmaraju, Ami B. Patel   +6 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program [PDF]

Discover Oncology
Background Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors.
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M. Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P. Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju   +38 more
doaj   +2 more sources

Prolonged, transplant-free remission with tagraxofusp in combination with venetoclax for transplant-ineligible blastic plasmacytoid dendritic cell neoplasm [PDF]

Leukemia Research Reports
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy predominantly affecting older adults. While the CD123-directed agent tagraxofusp has improved outcomes, durable long-term survival is typically limited to ...
Tia Cheunkarndee, Claire Schumann, Naveen Pemmaraju, Gabriel Mannis   +3 more
doaj   +2 more sources

Tagraxofusp: Expanding Therapeutic Horizons in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [PDF]

, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with limited treatment options. The development of tagraxofusp, a CD123-directed recombinant fusion protein, has revolutionized the management of BPDCN.
Dr sugreev Dwivedi Anuj Dwivedi, Dwivedi, Dr sugreev Dwivedi Anuj   +1 more
core   +1 more source

Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN

Hematology, Transfusion and Cell Therapy, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with cutaneous lesions which are often asymptomatic, can be solitary or multiple lesions, can be distributed widely, and may range from bruise-like lesions to ...
openaire   +3 more sources